Open access
Aug 2026
Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer
Bevacizumab is widely used as an anti-angiogenic maintenance therapy in ovarian cancer; however, there are currently no validated clinical criteria to guide patient selection for its use. To satisfy the urgent need for bevacizumab response biomarkers, we created a novel RNA-seq dataset (n = 244) and applied unsupervise...
O. Zolotareva, K. Legler, O. Tsoy et al.
· Genome Medicine · 0 citations